Evidence map›Paper›PMID 34904417›Full record

ArticleJournal of Zhejiang University. Science. B2021

Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer.

Xin Qi, Donghui Yan, Jiachen Zuo, Rui Wang, Jiajia Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin QiSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China. qixin@usts.edu.cn.
Donghui YanSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China.
Jiachen ZuoSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China.
Rui WangSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China.
Jiajia ChenSchool of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou 215011, China.

Funding

the National Natural Science Foundation of China 31900490 and 31770903the Natural Science Foundation of the Jiangsu Higher Education Institutions of China 19KJB180027
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the most lethal gastrointestinal cancer in both males and females worldwide (Sung et al., 2021). Because of the high heterogeneity of tumors, robust prognostic biomarkers are urgently needed in CRC management (Koncina et al., 2020). Chemokine signaling is a well-known pivotal player in immunity, inflammation, and cancer metastasis (Lacalle et al., 2017; Poeta et al., 2019; Do et al., 2020), and multiple genes involved in chemokine signaling have been demonstrated as potential prognostic biomarkers for CRC (Cabrero-De Las Heras and Martínez-Balibrea, 2018; Ottaiano et al., 2020; Yu et al., 2020). Therefore, the aim of our study was to develop a chemokine signaling-based multigene signature (CSbMgSig) that could effectively predict overall survival (OS) and therapeutic response for patients with CRC.

Indexed as

AdultAgedChemokinesColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm StagingPrognosisChemokinesChemokine signalingColorectal cancerMultigene signaturePrognosisTherapeutic response

Identifiers

PMID34904417
PMCPMC8669326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.